Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Paradigm4 has launched the Precision Cell AtlasTM as an integral component of its REVEALTM: SingleCell app. The Precision Cell Atlas enables scientists to create a custom cell atlas by selectively combining an unlimited number of samples from multiple datasets for specific research objectives and explicitly saving them for collaboration, reuse,
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
